We are a new biopharmaceutical company spin-out from the University of Cambridge with a first-in-class technology platform. We offer exciting science and business career opportunities for enthusiastic candidates who thrive on innovation, enjoy teamwork and want to make a difference to the lives of patients with life-changing diseases, such as cancer.
We are working in the exciting new field of targeted protein degradation, with a focus on discovery and development of novel biopharmaceuticals that selectively target cancer-causing proteins that have proved intractable using other drug classes. Our proprietary Polyproxin™ technology uses state-of-the-art bioinformatic and protein engineering techniques to discover drug candidates for preclinical and clinical studies.
We recently completed our Seed Financing with a syndicate of blue-chip healthcare investors and our research laboratories are at the Babraham Research Campus, Cambridge.